We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Pacific Biosciences of California (PACB - Free Report) was down 6.67% at $1.26. The stock trailed the S&P 500, which registered a daily loss of 1.67%. At the same time, the Dow lost 1.73%, and the tech-heavy Nasdaq lost 2.15%.
Shares of the maker of genetic analysis technology witnessed a loss of 24.16% over the previous month, trailing the performance of the Medical sector with its loss of 7.36%, and the S&P 500's loss of 6.15%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.17, reflecting a 13.33% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $41 million, indicating a 10.36% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.54 per share and revenue of $175.4 million, indicating changes of -1.89% and +9.62%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Pacific Biosciences of California. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Pacific Biosciences of California holds a Zacks Rank of #1 (Strong Buy).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Pacific Biosciences of California (PACB - Free Report) was down 6.67% at $1.26. The stock trailed the S&P 500, which registered a daily loss of 1.67%. At the same time, the Dow lost 1.73%, and the tech-heavy Nasdaq lost 2.15%.
Shares of the maker of genetic analysis technology witnessed a loss of 24.16% over the previous month, trailing the performance of the Medical sector with its loss of 7.36%, and the S&P 500's loss of 6.15%.
Analysts and investors alike will be keeping a close eye on the performance of Pacific Biosciences of California in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.17, reflecting a 13.33% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $41 million, indicating a 10.36% increase compared to the same quarter of the previous year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.54 per share and revenue of $175.4 million, indicating changes of -1.89% and +9.62%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Pacific Biosciences of California. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Pacific Biosciences of California holds a Zacks Rank of #1 (Strong Buy).
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.